本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 为进一步加强与投资者的互动交流，湖南华纳大药厂股份有限公司（以下简称 "公司"）将参加由湖南证监局、湖南省上市公司协会与深圳市全景网络有限公司 联合举办的"资本聚三湘 楚光耀新程——2025 年湖南辖区上市公司投资者网上 集体接待日暨半年度业绩说明会"活动，现将相关事项公告如下： 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 （https://rs.p5w.net），或关注微信公众号：全景财经，或下载全景路演 APP，参与 本次互动交流，活动时间为 2025 年 9 月 19 日（星期五）14:00-17:00。 届时，公司管理层将在线就公司经营业绩、公司治理、发展战略等投资者所关 心的问题，与投资者进行深入交流，欢迎广大投资者踊跃参与！ 特此公告。 证券代码：688799 证券简称：华纳药厂 公告编号：2025-076 湖南华纳大药厂股份有限公司 关于参加2025 年湖南辖区上市公司投资者网上集体接待日 暨半年度业绩说明会活动的公告 湖南华纳大药厂股份有限 ...

两融数据显示，该股最新融资余额为4.52亿元，近5日增加8116.80万元，增幅为21.92%。（数据宝） 9月10日华纳药厂大宗交易一览 华纳药厂9月10日大宗交易平台出现一笔成交，成交量11.59万股，成交金额547.20万元，大宗交易成交 价为47.20元，相对今日收盘价折价15.91%。该笔交易的买方营业部为国泰海通证券股份有限公司深圳 分公司，卖方营业部为广发证券股份有限公司沈阳小西路证券营业部。 证券时报·数据宝统计显示，华纳药厂今日收盘价为56.13元，上涨1.43%，日换手率为2.84%，成交额为 2.09亿元，全天主力资金净流出70.55万元，近5日该股累计下跌3.31%，近5日资金合计净流入4496.81万 元。 | 成交量 | 成交金额 | 成交价 | 相对当日收盘 | | | | --- | --- | --- | --- | --- | --- | | （万 | （万元） | 格 | 折溢价（%） | 买方营业部 | 卖方营业部 | | 股） | | （元） | | | | | 11.59 | 547.20 | 47.20 | -15.91 | 国泰海通证券股份有 | 广发证券股份有 ...

Core Viewpoint - The company reported a decline in revenue and net profit for the first half of 2025, attributed to intense market competition and policy impacts, but is optimistic about future growth through specialized marketing teams and ongoing R&D efforts [1][2]. Group 1: Financial Performance - In the first half of 2025, the company achieved revenue of 714 million yuan, a year-on-year decrease of 3.37% [1]. - The net profit attributable to shareholders was 71 million yuan, down 36.95% year-on-year; excluding stock incentive expenses, the net profit was 90 million yuan, a decline of 19.89% [1]. - Revenue from raw material products was 180 million yuan, an increase of 2.13% year-on-year, while revenue from formulation products was 522 million yuan, a decrease of 5.93% [1]. Group 2: Marketing and Sales Strategy - The company established three specialized marketing teams: Raw and Auxiliary Materials Division, New Drug Division, and Formulation Marketing Center [1]. - The New Drug Division achieved sales of 67 million yuan, a year-on-year increase of 34.46%, while the Formulation Marketing Center's sales were 455 million yuan, down 10.08% [1]. Group 3: Research and Development - R&D investment in the first half of 2025 was 80 million yuan, a year-on-year increase of 20.94%, accounting for 11.26% of revenue, up 2.26 percentage points from the previous year [2]. - The company is advancing its clinical pipeline, with the Qianqing Granules in Phase III trials and ZG-001 in Phase IIa trials, showing promising safety results [2]. - ZG-001 is projected to reach peak sales of 3.56 billion yuan by 2032, with an estimated market penetration of 15.0% [2]. Group 4: Profit Forecast - The company forecasts revenues of 1.474 billion yuan, 1.593 billion yuan, and 1.742 billion yuan for 2025, 2026, and 2027, respectively, with year-on-year growth rates of 4.30%, 8.07%, and 9.39% [3]. - The projected net profits for the same years are 141 million yuan, 170 million yuan, and 190 million yuan, with growth rates of -14.01%, 20.20%, and 11.83% [3]. - Corresponding EPS for these years are expected to be 1.08, 1.29, and 1.45 yuan, with PE ratios of 54.93, 45.70, and 40.87 times [3].

9月10日，华纳药厂大宗交易成交11.59万股，成交额547.2万元，占当日总成交额的2.55%，成交价47.2 元，较市场收盘价56.13元折价15.91%。 | 证券商除 华纳药厂 | 蓬券代码。 688799 | 成交价(元) 成交金额[万元] 成交量(*) 买入营业部 47.2 | 547.2 | 11.59 | 国泰海通证券股份 有限公司深圳分公 | 美出营业服 广发证券股份有限 公司沈阳小西路证 | 是否为专场 ea | | --- | --- | --- | --- | --- | --- | --- | --- | | 交易日期 025-09-10 | | | | | | | | ...

天眼查资料显示，华纳药厂成立于2001年04月30日，注册资本9380万人民币，法定代表人黄本东，注册 地址为湖南浏阳生物医药园区。主营业务为化学原料药、化学药制剂和中药制剂的研发、生产与销售。 目前，公司董事长为黄本东，董秘为乔桥，员工人数为1238人，实际控制人为黄本东。 雷达财经 文|冯秀语 编|李亦辉 9月7日，华纳药厂（证券代码：688799）发布公告称，其控股子公司上海致根医药科技有限公司通过增 资扩股引入战略投资者的事项已取得进展。根据公告，致根医药按照投前估值4亿元人民币获得了共计 6,999.8684万元的投资。此次增资事宜已经过公司董事会、监事会及股东大会审议通过，增资金额合计 不超过7,000万元。 目前，致根医药已完成工商变更登记，并取得了新的营业执照。 公司参股公司13家，包括湖南华纳大药厂手性药物有限公司、湖南华纳大药厂天然药物有限公司、湖南 华纳大药厂科技开发有限公司、湖南华纳大药厂医贸有限公司、湖南美和美诺生物技术有限公司等。 在业绩方面，公司2024年至2025(Q2)年营业收入分别为14.13亿元、3.36亿元和7.14亿元，同比分别增 长-1.38%、-9.83%和-3. ...

Group 1 - Junshi Biosciences' anti-IL-17A monoclonal antibody (JS005) achieved positive results in a Phase III clinical trial for moderate to severe plaque psoriasis, with both primary and key secondary endpoints showing statistical significance and clinical relevance. The company plans to submit a marketing authorization application soon [1] - Warner Pharmaceuticals announced that its subsidiary, Shanghai Zhigen Pharmaceutical Technology Co., Ltd., will introduce strategic investors for a capital increase not exceeding 70 million yuan, which will support the clinical trials of its innovative drugs, including ZG-001 and ZG-002 [2] - Sunflower is planning a major asset restructuring to acquire controlling stakes in Zhangzhou Xipu Material Technology Co., Ltd. and 40% of Zhejiang Beid Pharmaceutical Co., Ltd., aiming to enhance its competitiveness in the pharmaceutical sector and enter the new materials field [3] Group 2 - Huaxi Biological's controlling shareholder, Huaxi Xinyu Investment Co., Ltd., plans to increase its stake in the company with an investment of no less than 200 million yuan and no more than 300 million yuan, having already exceeded the lower limit of the planned increase. This move reflects confidence in the company's long-term development [4] - Eli Lilly has initiated a Phase I clinical trial for its weight loss drug LY4064912, which has no disclosed mechanism target yet. This step underscores the company's commitment to the metabolic field and aims to solidify its leading position in the obesity treatment market [5]

湖南华纳大药厂股份有限公司于2025年4月18日召开董事会及监事会，审议通过控股子公司上海致根医 药科技有限公司增资扩股引入战略投资者的议案，并于2025年5月12日经年度股东大会批准。致根医药 本轮引入战略投资者，投资方按投前估值4亿元人民币，合计投资6,999.8684万元，以认购增资方式投 入。近日，致根医药已完成工商变更登记，取得上海市浦东新区市场监督管理局颁发的《营业执照》。 变更后注册资本为人民币205.5572万元，公司名称、住所、法定代表人等信息不变。经营范围包括技术 服务、技术开发、生物化工产品研发、医学研究等。华纳药厂董事会保证公告内容真实、准确、完整， 无虚假记载、误导性陈述或重大遗漏。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 来自交易信息汇总：9月5日主力资金净流出536.76万元，游资资金净流出1055.97万元，散户资金 净流入1592.73万元。 来自公司公告汇总：控股子公司上海致根医药完成增资扩股工商变更，投前估值4亿元，战略投资 者合计投资6,999.8684万元。 9月5日主力资金净流出5 ...

证券代码：688799 证券简称：华纳药厂 公告编号：2025-075 湖南华纳大药厂股份有限公司 关于控股子公司增资扩股引入战略投资者 暨关联交易的进展公告 公司名称：上海致根医药科技有限公司 统一社会信用代码：91310115MA7DDX598D 类型：有限责任公司（自然人投资或控股） 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、本次交易概述 湖南华纳大药厂股份有限公司（以下简称"公司"、"华纳药厂"）于 2025 年 4 月 18 日召开第四届董事会第一次会议及第四届监事会第一次会议、于 2025 年 5 月 12 日召开 2024 年年度股东大会，审议通过了《关于控股子公司增资扩股 引入战略投资者暨关联交易的议案》，同意控股子公司上海致根医药科技有限公 司（以下简称"致根医药"）引入战略投资者进行增资扩股，增资金额合计不超 过 7,000 万元。具体内容详见公司于 2025 年 4 月 22 日在上海证券交易所网站 （www.sse.com.cn）披露的《湖南华纳大药厂股份有限公司关于控股子公司增资 扩股引 ...

Core Viewpoint - Warner Pharmaceuticals reported a decline in revenue and net profit for the first half of 2025, influenced by market conditions, while actively developing innovative drug candidates with significant potential [1][2][3] Financial Performance - The company achieved revenue of 714 million yuan, a year-on-year decrease of 3.37% [1] - The net profit attributable to shareholders was 71.12 million yuan, down 36.95% year-on-year; excluding stock incentive expenses, the net profit was 90.36 million yuan, a decrease of 19.89% [1] Innovative Drug Development - ZG001, an antidepressant, is in Phase IIa clinical trials, showing excellent safety with no severe adverse reactions and rapid absorption [1] - ZG002, a new drug for autoimmune diseases, demonstrated 2-4 times the in vitro activity of the already marketed BMS-986165 and is set to enter Phase I clinical trials for moderate to severe plaque psoriasis [2] - The company is advancing its traditional Chinese medicine pipeline, including the innovative drug Qianqing Granules, which has shown good safety and stable efficacy in Phase II trials and is moving to Phase III trials [2] R&D and Regulatory Progress - The company made significant progress in generic and raw material drug development, obtaining six drug registration approvals and five raw material approvals during the reporting period [2] - The company has submitted nine formulation product registration applications and completed three consistency evaluations [2] Profit Forecast - Revenue projections for 2025-2027 are 1.384 billion, 1.431 billion, and 1.500 billion yuan, with growth rates of -2.02%, 3.35%, and 4.85% respectively [3] - Net profit forecasts for the same period are 122 million, 184 million, and 204 million yuan, with growth rates of -25.72%, 50.96%, and 10.73% respectively [3]

Group 1 - Huida Sanitary Ware plans to publicly transfer 100% equity and debt of Guangxi Xingaosheng, with debt amounts of 132 million and 138 million yuan as of June 30, 2025 [1] - Sainuo Medical received administrative regulatory measures from Tianjin Securities Regulatory Bureau due to inaccurate information disclosure in quarterly reports [2][3] - Jiangling Motors reported August vehicle sales of 30,003 units, a year-on-year increase of 8.92% [6] Group 2 - Jimin Health's controlling shareholder plans to reduce its stake by up to 3%, totaling 15.75 million shares [7] - Satellite Chemical announced routine maintenance of polyethylene and ethylene glycol facilities, expected to last 45 days [8] - Hubei Yihua's 200,000-ton caustic soda project has been successfully put into production [10] Group 3 - Shanghai Pharmaceuticals' Dihydroxypropyl Theophylline Injection has passed the consistency evaluation for generic drugs [13] - Ningbo Construction's subsidiaries won construction projects worth 1.117 billion yuan [16] - Wens Foodstuff reported August sales revenue of 4.825 billion yuan from live pigs, with a year-on-year decrease in revenue and price [28] Group 4 - Long-term Logistics announced the resignation of its deputy general manager due to personal reasons [44] - Huaming Equipment proposed a cash dividend of 2 yuan per 10 shares, totaling 179 million yuan [46] - Transsion Holdings plans to distribute a cash dividend of 0.8 yuan per share [49]